XML 55 R42.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value Accounting - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2020 | Jan. 31, 2016 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2018
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Change in contingent consideration |  |  |  |  | $ 957,000 | $ 3,188,000 |
Minimum |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range |  |  |  |  | 12.20% |  |
Maximum |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range |  |  |  |  | 13.50% |  |
Integrated Diagnostics, Inc |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Fair value of contingent consideration recognized on acquisition date |  |  |  |  |  |  | $ 19,600,000
Change in contingent consideration resulting from the accretion of the liability offset |  |  | $ 1,000,000.0 |  | $ 2,900,000 |  |
Change in contingent consideration due to the impact of the deceleration of expected revenue and decreases in expected costs |  |  | 0 |  | 1,900,000 |  |
Change in contingent consideration |  |  |  |  |  | 3,200,000 |
Change in contingent consideration resulting from the impact of the acceleration of expected revenue and decreases in expected costs |  |  |  |  |  | 700,000 |
Change in contingent consideration resulting from accretion of liability |  |  |  | $ 900,000 |  | $ 2,500,000 |
Series F Preferred Stock |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Calculated number of contingent value rights received by investors, if financing raised exceed the amount |  | $ 20,202,323 |  |  |  |  |
Contingent value rights shares |  | 3,999 |  |  |  |  |
Contingent value rights | $ 0 | $ 500,000 | 0 |  | 0 |  |
Net proceeds percentage of cash payment to the CVR holders |  | 15.00% |  |  |  |  |
Development and regulatory costs payable | $ 300,000 |  | $ 300,000 |  | $ 300,000 |  |
Drug Ficlatuzumab | Series F Preferred Stock |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Contingent value right, percentage multiplier |  | 0.00375% |  |  |  |  |
AVEO Oncology | Series F Preferred Stock |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |
Percentage of development and regulatory costs exercised using opt-out right | 50.00% |  |  |  |  |  |

X
- Definition Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability due to the impact of the deceleration of expected revenue and decreases in expected costs. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityDueToImpactOfDecelerationOfExpectedRevenueAndDecreasesInExpectedCosts
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability resulting from accretion of liability. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityResultingFromAccretionOfLiability
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability resulting from accretion of liability offset. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityResultingFromAccretionOfLiabilityOffset
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability resulting from the impact of the acceleration of expected revenue and decreases in expected costs. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityResultingFromImpactOfAccelerationOfExpectedRevenueAndDecreasesInExpectedCosts
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Calculated number of contingent value rights received by investors, if financing raised exceed the amount. + References No definition available. + Details
Name: | bdsx_CalculatedNumberOfContingentValueRightsReceivedByInvestorsIfFinancingRaisedExceedAmount
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent value right, percentage multiplier. + References No definition available. + Details
Name: | bdsx_ContingentValueRightPercentageMultiplier
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent value rights. + References No definition available. + Details
Name: | bdsx_ContingentValueRights
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights shares. + References No definition available. + Details
Name: | bdsx_ContingentValueRightsShares
Namespace Prefix: | bdsx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Development and regulatory costs payable. + References No definition available. + Details
Name: | bdsx_DevelopmentAndRegulatoryCostsPayable
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Net proceeds percentage of cash payment to the cvr holders. + References No definition available. + Details
Name: | bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development and regulatory costs exercised using opt-out right. + References No definition available. + Details
Name: | bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of probabilities of contingent consideration successful achievement milestone discount rates range. + References No definition available. + Details
Name: | bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value of contingent consideration in a business combination that is classified in shareholders' equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=bdsx_DrugFiclatuzumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |